trending Market Intelligence /marketintelligence/en/news-insights/trending/om7hs_yg-x6logx_wzkgow2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Bone Biologics enters stock, debt purchase agreement with Hankey Capital

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Bone Biologics enters stock, debt purchase agreement with Hankey Capital

Bone Biologics Corp. agreed to sell up to 3,869,979 common shares at $1 each to Hankey Capital LLC.

The Burlington, Mass.-based medical device company also agreed to issue a convertible secured note due Dec. 31, 2019, worth up to $2 million.

The note is convertible into Bone Biologics common stock at $1 per share and will have an interest at a prime rate or 8.5% annually, whichever is greater.

The purchase agreement with Hankey Capital will close on the later of July 16, or when the company implements its 1-for-10 reverse stock split.